# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

> **NCT02852395** · PHASE1 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 90 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-48816274
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02852395
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-13
- **Primary completion:** 2018-05-02
- **Final completion:** 2018-05-02
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02852395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02852395, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02852395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*